Head to head
Ingevity vs Linde
Side-by-side on the measures that matter, with a plain-English read. Full detail: NGVT · LIN
NGVT
Ingevity
70.92-2.58%
1-year price shape — +33% over the period
Quant Rating B · 70/100
vs
LIN
Linde
483.98-1.22%
1-year price shape — +4% over the period
Quant Rating D · 45/100
1-year performance, rebased to 100
Linde edges it on the scoreable measures. Linde trades cheapest on trailing earnings; Linde pays the highest dividend yield; Linde earns the most per share.
| NGVT | LIN | |
|---|---|---|
| Snapshot | ||
| Sector | Specialty Chemicals | Specialty Chemicals |
| Last price | 70.92 | 483.98 |
| Change today | -2.58% | -1.22% |
| 1-year return | +32.7% | +4.3% |
| Market cap | $2.44B | $223.11B |
| 52-week range | 45.85 – 79.29 | 384.00 – 546.40 |
| Valuation | ||
| P/E (TTM) | 46.66 | 31.22 |
| P/E percentile, own 5-yr range | 99th | 8th |
| P/B | 51.99 | 5.71 |
| Dividend yield | 0.00% | 1.28% |
| Profitability & growth | ||
| EPS (TTM) | -4.61 | 14.61 |
| Net profit (TTM) | $-158.48M | $6.73B |
| Revenue (TTM) | $1.16B | $35.45B |
| Revenue growth (YoY) | -5.2% | +9.3% |
| Gross margin | 41.1% | 48.3% |
| Operating margin | 24.5% | 27.1% |
| Net margin | 4.7% | 20.4% |
| Free cash flow (TTM) | $154.90M | $4.98B |
| Ownership & sentiment | ||
| Institutional ownership | 103.1% | 88.0% |
| Insider activity (12mo) | 29 buy / 21 sell | 33 buy / 13 sell |
| Short interest (% of float) | 4.2% | 1.3% |
| Analyst consensus | 100% buy (1) | 87% buy / 13% hold (15) |
| Analyst price target | $85 (+20%) | $557 (+15%) |
| StockVane view | ||
| StockVane Quant Rating | B (70) | D (45) |
| Company | ||
| Employees | 1,700 | 65,177 |
| Founded | 2015 | 2017 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.